1. Home
  2. RIGL vs KNOP Comparison

RIGL vs KNOP Comparison

Compare RIGL & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • KNOP
  • Stock Information
  • Founded
  • RIGL 1996
  • KNOP 2013
  • Country
  • RIGL United States
  • KNOP United Kingdom
  • Employees
  • RIGL N/A
  • KNOP N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • KNOP Marine Transportation
  • Sector
  • RIGL Health Care
  • KNOP Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • KNOP Nasdaq
  • Market Cap
  • RIGL 247.1M
  • KNOP 235.1M
  • IPO Year
  • RIGL 2000
  • KNOP 2013
  • Fundamental
  • Price
  • RIGL $25.04
  • KNOP $6.23
  • Analyst Decision
  • RIGL Buy
  • KNOP
  • Analyst Count
  • RIGL 5
  • KNOP 0
  • Target Price
  • RIGL $31.30
  • KNOP N/A
  • AVG Volume (30 Days)
  • RIGL 288.9K
  • KNOP 56.9K
  • Earning Date
  • RIGL 11-07-2024
  • KNOP 12-04-2024
  • Dividend Yield
  • RIGL N/A
  • KNOP 1.69%
  • EPS Growth
  • RIGL N/A
  • KNOP N/A
  • EPS
  • RIGL 0.22
  • KNOP N/A
  • Revenue
  • RIGL $157,374,000.00
  • KNOP $296,181,000.00
  • Revenue This Year
  • RIGL $38.26
  • KNOP $6.70
  • Revenue Next Year
  • RIGL $24.21
  • KNOP $2.79
  • P/E Ratio
  • RIGL $109.79
  • KNOP N/A
  • Revenue Growth
  • RIGL 21.65
  • KNOP 5.27
  • 52 Week Low
  • RIGL $7.48
  • KNOP $4.94
  • 52 Week High
  • RIGL $29.82
  • KNOP $9.11
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.80
  • KNOP 50.68
  • Support Level
  • RIGL $22.33
  • KNOP $6.13
  • Resistance Level
  • RIGL $29.16
  • KNOP $6.32
  • Average True Range (ATR)
  • RIGL 2.30
  • KNOP 0.17
  • MACD
  • RIGL 0.41
  • KNOP 0.04
  • Stochastic Oscillator
  • RIGL 69.96
  • KNOP 80.43

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

Share on Social Networks: